The leukocyte receptor CD62, which is expressed on activated platelets and endothelial cells, is shown to mediate cell adhesion by binding a sialylated carbohydrate structure, sialyl-Lewis x, found on neutrophils, monocytes, and tumor cells. This structure has previously been identified as the ligand for another member of the LEC-CAM family of cell adhesion molecules, endothelial cell-eukocyte adhesion molecule 1, which also binds neutrophils and monocytes. The results demonstrate that although the two LEC-CAMs differ in their biological activities by their distribution and mode of expression, they are capable of mediating cell adhesion by recognition of the same carbohydrate ligand.
Leukocyte trafficking and recruitment to sites of inflammation are mediated by three adhesion receptor families, the integrin and immunoglobulin superfamilies and the recently described LEC-CAM, or selectin family (1) (2) (3) (4) . The known LEC-CAMs, LEC-CAM-1 (Mel-14/LAM-1), endothelial cell-leukocyte adhesion molecule 1 (ELAM-1), and CD62 [140-kDa granule membrane protein (GMP-140)/platelet activation-dependent granule external membrane protein (PADGEM)], contain an N-terminal lectin domain that mediates adhesion by binding carbohydrate ligands on opposing cells. The lectin domain is followed by an epidermal growth factor-like domain and a series of consensus repeats similar to those found in complement regulatory proteins. A flurry of recent reports have focused on the identification of the carbohydrate ligands recognized by ELAM-1 and CD62 (5) (6) (7) (8) (9) (10) (11) (12) . These two LEC-CAMs are expressed on activated endothelial cells (ELAM-1 and CD62) and platelets (CD62) and are implicated in the recruitment of neutrophils and monocytes to sites of tissue injury.
Evidence from several groups has defined the functional ligand of ELAM-1 as a terminal structure found on glycoprotein and glycolipid carbohydrate groups that contain both sialic acid (Sia) and fucose (Fuc), as typified by sialyl-Lewis x (SLex; refs. 5-9).
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Larsen et al. (10) have proposed that CD62 recognizes the nonsialylated Lewis x structure (Lex or CD15) since neutrophil adhesion to activated platelets is inhibited both by monoclonal antibodies (mAbs) to Lex (anti-CD15) and by oligosaccharides containing the Lex structure. However, other groups have suggested that sialic acid is a crucial determinant of the natural ligand since treatment of neutrophils with sialidase abolishes their ability to adhere to CD62 (11, 12) . Both pieces of information suggested that the ELAM-1 ligand, SLex, is a logical candidate as a sialylated ligand that could mediate cell adhesion by CD62. EXPERIMENTAL PROCEDURES Cell Isolation and Culture. Platelets were obtained from a normal human donor and washed free of plasma proteins in the presence of prostaglandin E1 (100 nm) (13) . Neutrophils were isolated from fresh human blood by centrifugation at room temperature through mono-poly resolving medium (Flow Laboratories) followed by three washes in ice-cold Hanks' balanced salt solution (GIBCO) containing 20 mM Hepes (GIBCO) and 0.2% glucose (Fisher). Human umbilical vein endothelial cells were obtained as described (6) . HL-60 cells were cultured in RPMI 1640 containing 10%6 fetal calf serum. Chinese hamster ovary (CHO-Ki) cells, glycosylation mutants LEC1l and LEC12 (14) (15) (16) (17) (18) (19) , and the carcinoma line (COLO-205) were cultured in the a modification of Eagle's minimal essential medium (a-MEM) containing ribonucleosides, deoxyribonucleosides, and 10%1o fetal calf serum.
Assays for CD62-Mediated Adhesion to Activated Platelets. Two assays were used, a fluid phase assay and a plate assay. The fluid phase assay (see Figs. 2-4) was performed essentially as described (10) for PADGEM (CD62). Platelets at 2 x 108 per ml were activated with thrombin at 0.25 units/ml for 20 min at room temperature without stirring. Twenty microliters of the activated platelet suspension was then mixed with an equal volume ofa suspension ofthe cells (2 x 106 cells per ml) to be assessed for adhesion. Adhesion was evaluated microscopically and was scored as the percent ofthe test cells that had bound two or more platelets. The plate assay used was a modification of the endothelial cell-neutrophil adherence assay previously described (20) . A IlTo whom reprint requests should be addressed at *.
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plate was incubated at 370C for 15 min, centrifuged for 2 min at 90 x g, and then washed twice with phosphate-buffered saline (PBS) to remove nonadherent platelets. To block platelet Fc receptors, 300 pl of heat-aggregated IgG (20 pug/ml) was added to each well, and the plate was incubated at 370C for 15 min. HL-60 cells were radiolabeled with 51Cr
[450 ,Ci (1 Ci = 37 GBq) was added to 3 x 106 cells in 300
Al and incubated for 60 min at 37'C1, washed three times in RPMI 1640 containing 10%o fetal calf serum, and resuspended to 4 x 106 per ml. This suspension (100 Al) was added to 1.6 ml of RPMI 1640 with or without mAb, and the mixture was incubated for 30 min at 370C with gentle agitation. At the end of the incubation period, 300 A.l of this cell suspension was added to triplicate wells of the assay plate containing bound, activated platelets. The plate was centrifuged for 2 min at 90 x g and then allowed to stand for 5 min at room temperature. Unbound cells were removed by three washes with PBS, and the remaining bound cells were removed from the plate with an SDS-containing buffer and then processed for radioactive counting. Adherence was scored as the percent of total HL-60 cells bound.
Assay for ELAM-l-Mediated Adhesion. ELAM-1-mediated adhesion of neutrophils to activated endothelial cells was performed essentially as described (6), with the modifications that the assay was performed at 370C for 5.5 min and the assay wells were washed vigorously by inverting the plate and refilling four times with a repeating pipet. Adhesion was quantitated by spectrophotometric analysis of myeloperoxidase (21) . The degree of ELAM-1-mediated adhesion was confirmed with the mAb for ELAM-1, P6E2, which inhibited neutrophil binding to activated endothelial cells by 80o.
Preparation of Glycolipid-Containing Liposomes. Liposomes containing glycolipids (glycolipid liposomes) were prepared as described (6) . Briefly, 100 ,Ag of glycolipid was added to 500 ,g of phosphatidylcholine (egg yolk; Sigma) and 300 ,g of cholesterol (Sigma) in chloroform/methanol, 2:1, and the mixture was evaporated to dryness with N2. Before use, the pellet was dissolved in 100 Al of absolute ethanol and sonicated. PBS (1.9 ml) was added, and the mixture was sonicated for an additional 10 min. Structures of the various glycolipids examined are as follows: nLC6, Gal,81-4GIcNAc,81-3Gal,81-4GlcNAc,81-3Gal/31-4Glc,81-1 ceramide (Cer); SH, Siaa2-3Gal81-4GlcNAc,81-3Gal,81-4GlcNAcf31-3Gal,81-4Glcf31-lCer; diLex, Gal/31-4(Fucal-3)GlcNAcj31-3Gal/31-4(Fucal-3)GlcNAc,81-3Gal,81-4Glc81-lCer; SdiLex, Siaa2-3Gal,81-4(Fucal-3)GlcNAcf31-3Gal,81-4(Fucal-3)GlcNAcJ1-3Gal,81-4Glcl1-lCer; SLex, Siaa2-3Gal/31-4(Fucal-3)GlcNAcf81-3Gal,81-4Glc,81-lCer; SPG, Siaa2-3Gal,81-4GlcNAc,31-3Galf31-4Glcf31-lCer.
Oligosaccharides. Lacto-N-fucopentaose I (LNF I) and Lacto-N-fucopentaose III (LNF III) isolated from human milk were purchased from Calbiochem and were >95% pure by HPLC as assayed by the supplier. A synthetic hexasaccharide containing the terminal SLex structure (22) was the generous gift of A. Hasegawa, Gifu University, Japan. Structures of the oligosaccharides are as follows: LNF I, Fucal2Galf81-3GlcNAc/31-3Galf31-4Glc; LNF III, Gal,81-4(Fucal-3)GlcNAcj31-3Galf31-4Glc; SLex-hex, NeuAca2-3GalP1-4(Fucal-3)GlcNAc,81-3Gal,31-4Glc-O-CH2CH2SiMe3.
Carbohydrate-Specific mAbs. mAbs to SLex and Lex (6) ' . In experiments in which mAbs to Lex and SLex were evaluated for their ability to inhibit CD62-mediated adhesion of neutrophils to activated platelets, mAbs to Lex inhibited slightly, whereas mAbs to SLex inhibited almost completely (Fig. 1) . The results confirm previous reports that mAbs to Lex give partial inhibition of CD62 adhesion (10, 12) . The more complete inhibition with the mAbs to SLex suggested that SLex may be a high-affinity ligand of CD62.
CD62-Mediated Adhesion of SLex-Containing Cells to Activated Platelets. Examination of CHO cells and glycosylation mutants LEC11 and LEC12 (14) (15) (16) (17) (18) (19) provided evidence that SLex could support CD62-mediated adhesion to activated platelets, whereas Lex could not. Indeed, wild-type cells (CHO-Ki), which express neither SLex nor Lex, and LEC12 cells, which express only Lex, were not bound. In contrast, LEC11 cells, which express the SLex determinant, were bound almost as well as the promyelocytic HL-60 cells used as a positive control (Fig. 2A) . Sialidase treatment of LEC11 cells or neutrophils to convert SLex to Lex abolished their adherence to activated platelets, further showing that Lex alone is not sufficient for mediating adhesion by CD62 (Fig.  2B) . A carcinoma cell line (COLO-205) that contains SLex (18) also bound to activated platelets and, like the other cells, its adhesion was abolished by sialidase treatment (Fig. 2B) .
Inhibition of CD62-Mediated Adhesion by Glycolipid Liposomes. Since Lex oligosaccharides were previously reported to inhibit CD62-mediated cell adhesion of activated platelets (10), we used a similar assay to compare liposomes containing glycolipids with the Lex and SLex structures for their ability to prevent adhesion of HL-60 cells and human neutrophils. HL-60 cell adhesion (Fig. 3A) was partially inhibited (50%) by liposomes containing Lex at the highest concentration tested (5 ;kg/ml). In contrast to partial inhibition obtained adhesion was less sensitive and was observed only with SLeX (Fig. 3B) .
Inhibition FIG. 5. CD62 and ELAM-1 exhibit similar specificity for SLeX as a high-affinity ligand. Liposomes containing various glycolipids of related structure were evaluated for their ability to inhibit neutrophil adhesion to activated platelets (CD62) and interleukin 1x8-activated endothelial cells. Structures are indicated at the left in symbol form, and the SLeX determinant found in two of the glycolipids is highlighted in the rectangular box. <, Sia; O, Fuc; o, Gal; m, GlcNAc. CD62-dependent adhesion of neutrophils to thrombin-activated platelets was performed by the fluid-phase assay. Liposome-induced inhibition of ELAM-1-mediated cell adhesion to activated endothelial cells was performed as described in Experimental Procedures.
ELAM-1-mediated adhesion of neutrophils to interleukin 1/3-activated human vascular endothelial cells (Fig. 5) . For each assay the concentration of liposomes used was fixed empirically as the concentration that gave maximal inhibition when SLeX glycolipid was used-namely, 2 ,ug/ml for CD62 and 14 ,ug/ml for ELAM-1. Under conditions ofthe assays used in the present study, the specificity of the two LEC-CAMs was virtually identical for the glycolipid structures tested, being inhibited only by those containing the SLeX structure.
DISCUSSION
The potential significance of CD62 and ELAM-1 mediating cell adhesion through the same carbohydrate ligand can be inferred from emerging information on the biological roles of these receptors. These LEC-CAMs mediate adhesion of neutrophils and monocytes to vascular endothelial cells and platelets, but in different biological contexts (23) (24) (25) (26) . CD62 is stored in intracellular secretory granules of endothelial cells and platelets and is rapidly expressed on the cell surface following degranulation, within minutes of exposure to activating agents such as thrombin, histamine, or phorbol esters (23, 24) . In contrast, ELAM-1 is expressed only on endotheHal cells and requires de novo synthesis (1-4 hr) following induction by inflammatory cytokines such as interleukin 1/3 and tumor necrosis factor (25) . Since CD62 is expressed on both platelets and endothelial cells, it has been proposed that this adhesion receptor may provide a link between the hemostatic and inflammatory responses (24, 26 (10) demonstrated that an oligosaccharide containing the nonsialylated analog, Lex (LNF III), was capable of inhibiting CD62-mediated adhesion. This observation is completely consistent with results presented in this report that suggest that Lex is a low-affinity ligand of CD62 (Fig. 4 ), but will not by itself support cell adhesion (refs. 11 and 12; Fig. 2) .
Tiemeyer et al. (8) have proposed that the natural ligand for ELAM-1 is a variation of SLex referred to as CD65, or VIM-2, where the fucose is two sugars further removed from the sialic acid.
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The glycolipid SdiLex (27) , previously shown to be an inhibitor of ELAM-1 (6), incorporates both the SLex and CD65 structures (see Fig. 5 ). However, the shorter chain SLex glycolipid examined in this report does not incorporate the CD65 structure, yet it inhibits ELAM-1-mediated adhesion and CD62-mediated adhesion (Fig. 5) . Thus, the SLex structure appears to be sufficient to mediate high-affinity interactions with both LEC-CAMs. Although both CD62 and ELAM-1 exhibit similar specificities toward the carbohydrate structures examined in this report, it is premature to conclude that they have identical specificities for cell surface receptor molecules. Although the SLex structure is found to terminate both glycoprotein and glycolipid carbohydrate groups of human neutrophils, it has not been established if either or both serve as biologically relevant neutrophil ligands. It is possible, however, that recognition of protein epitopes by either LEC-CAM could modify their ligand specificity enabling them to recognize specific glycoproteins. In this regard, however, it is of interest to note that LEC11 cells and COLO-205, which have no myeloid-specific proteins, are capable of participating in LEC-CAM-mediated cell adhesion. Further, it has been recently demonstrated that binding of neutrophils to soluble GMP-140 is not inhibited by synthetic SLex-bovine serum albumin conjugates (12) . The underlying basis for this observation is not clear and may reflect the fine specificity of GMP-140 for SLeX-containing carbohydrate groups on glycoproteins and glycolipids. Finally, recent reports have demonstrated that skin-homing T cells bind ELAM-1 even though T cells do not appear to contain the SLex ligand (28) (29) (30) (31) . These data suggest that ELAM-1 may additionally recognize a carbohydrate ligand other than SLex. Further information on the fine specificities of ELAM-1 and CD62 will be required to determine if these two LEC-CAMs have identical or merely overlapping specificities for their carbohydrate ligands.
Note Added in Proof. Since SdiLex-and SLex-containing glycolipids were prepared from precursors derived from bovine erythrocytes, the sialic acids were 85% N-glycollylneuraminic acid and 15% N-acetylneuraminic acid. In separate experiments, SLex glycolipids containing only N-acetylneuraminic acid were found to be equipotent to the SLex glycolipids used in this report.
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